Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab

Leuk Lymphoma. 2015 Mar;56(3):779-81. doi: 10.3109/10428194.2014.927461. Epub 2014 Jul 23.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use
  • Combined Modality Therapy
  • Female
  • Fever / etiology
  • Headache / etiology
  • Humans
  • Iodine Radioisotopes / adverse effects
  • Iodine Radioisotopes / therapeutic use
  • Kaplan-Meier Estimate
  • Lymphoma, Follicular / pathology
  • Lymphoma, Follicular / therapy*
  • Male
  • Middle Aged
  • Nausea / etiology
  • Neoplasm Recurrence, Local
  • Radioimmunotherapy / methods
  • Rituximab / adverse effects
  • Rituximab / therapeutic use*
  • Thrombocytopenia / etiology
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Iodine Radioisotopes
  • Rituximab
  • tositumomab I-131

Associated data

  • ClinicalTrials.gov/NCT00268983